ABSTRACT
Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Consortium on Neurodegeneration in Aging commissioned Work Groups to review evidence on the efficacy, and safety of these new therapies, as well as their projected impacts on Canadian dementia systems of care. We included persons with lived experience with Alzheimer disease in the discussion about the benefits and harms. Our review of the trial publications found strong support for statistically significant group differences, but also recognized that there are mixed views on the clinical relevance of the observed differences and the value of therapy for individual patients. The drugs are intended for persons with early AD, at a stage of mild cognitive impairment or mild dementia. If patients are treated, then confirmation of AD by positron emission tomography or cerebrospinal fluid analysis and monitoring for risk of amyloid-related imaging abnormalities was recommended, as done in the clinical trials, although it would strain Canadian resource capacity. More data are needed to determine the size of the potentially eligible treatment population in Canada.
Competing Interest Statement
AmanPreet Badhwar reports a grant from the Alzheimer Society of Canada, paid to her institution. Laura Barlow reports no disclosures. Robert Bartha reports no disclosures. Sarah Best reports honoraria from Eisai pharmaceuticals, paid to her. Jennifer Bethell reports no disclosures. Jaspreet Bhangu reports a contract from Eisai for site PI, paid to his institution; consulting for Eisai, unpaid; and consulting for Eli Lilly, paid to him. Sandra Black reports contracts with Genentech, Optina, Roche, Eli Lilly, Eisai/Biogen Idec, Novo Nordisk, Lilly Avid, and ICON, paid to her institution; grants from the Ontario Brain Institute, CIHR, Leducq Foundation, Heart and Stroke Foundation of Canada, NIH, Alzheimers Drug Discovery Foundation, Brain Canada, Weston Brain Institute, Canadian Partnership for Stroke Recovery, Canadian Foundation for Innovation, Focused Ultrasound Foundation, Alzheimers Association US, Queens University, Compute Canada Resources for Research Groups, CANARIE, and Networks of Centres of Excellence of Canada, paid to her institution; consulting for Novo Nordisk, Eisai, Eli Lilly, Roche, and Cpd network, paid to her; consulting for DSR: Diagnosis, Solutions & Results Inc., Conference Board Canada, World Dementia Council, University of Rochester Contribution to the Mission and Scientific Leadership of the Small Vessel VCID Biomarker Validation Consortium, National Institute of Neurological Disorders and Stroke, and Ontario Dementia Care Alliance (ODCA), paid to her institution; honoraria from Biogen, Roche, and Eisai, paid to her; and honoraria from Roche, unpaid. Christian Bocti reports stock in Imeka. Michael Borrie reports consulting for Eisai, Eli Lilly, Biogen, and Hoffmann-La Roche, paid to him; and contracts with Eisai, Eli Lilly, Biogen, Hoffmann-La Roche, and Alector, paid to his institution. Susan Bronskill reports grants from the Alzheimer Society of Canada, Brain Canada Foundation, Evaluative Clinical Sciences Research Platform of Sunnybrook Research Institute, Canadian Consortium on Neurodegeneration in Aging (CCNA), Canadian Institutes of Health Research, and Ontario Brain Institute, paid to her institution; and a contract with the Public Health Agency of Canada, paid to her institution. Amer Burhan reports a contract with the Toronto Memory Program (Headland Research), paid to him; consulting for Eisai, Avanir, Otsuka-Lundbeck, Boehringer-Ingelheim, and Roche Pharma, paid to him; and grants from the National Institute of Aging, Brain Canada Foundation, Alzheimer Drug Discovery Foundation, National Research Council, Weston Foundation, and Canada Institute for Health Research, paid to his institution. Frederic Calon reports meeting expenses from Eli Lilly, unpaid. Barry Campbell reports no disclosures. Howard Chertkow reports contracts as site PI for clinical trials with Hoffmann-La Roche Limited, TauRx, Eli Lilly Corp., Anavex Life Sciences, Alector LLC, Biogen MA Inc., IntelGenX Corp., and Immunocal, paid to his institution; and consulting for Eisai, Biogen, and Lilly Inc. in Canada, paid to his institution. D. Louis Collins reports no disclosures. Mahsa Dadar reports no disclosures. Mari DeMarco reports consulting for Roche and Eisai, paid to her; honoraria from Roche, paid to her; and a grant from Roche, paid to her institution. Philippe Desmarais reports consulting for Eisai, paid to him. Simon Ducharme reports contracts for clinical trials with Biogen, Janssen, Novo Nordisk, Alnylam, Passage Bio, and Innodem Neurosciences, paid to his institution; consulting for QuRALIS, Eisai, and Eli Lilly, paid to him; honoraria from Eisai, paid to him; and participation in a Data Safety Monitoring Board or Advisory Board for Aviado Bio and IntelGenX, paid to him. Simon Duchesne reports stock or stock options for True Positive Medical Devices Inc., paid to him; honoraria from Novo Nordisk, paid to him; and travel expenses from Eisai, paid to him. Gillian Einstein reports no disclosures. Howard Feldman reports consulting for Eisai Inc., Biogen, LuMind, and Novo Nordisk, paid to his institution; grants from Allyx Therapeutics, Vivoryon Therapeutics, Biohaven Pharmaceuticals, and LuMind Foundation, paid to his institution; royalties from the University of British Columbia, paid to him; a patent held by the University of British Columbia, paid to him; consulting for Axon Neuroscience, Arrowhead Pharmaceuticals, and Biosplice Therapeutics, paid to his institution; support for attending meetings or travel from Novo Nordisk Inc., Royal Society of Canada, Translating Research in Elder Care (TREC), and the Association for Frontotemporal Dementia (AFTD), with payments made to his institution; participation in a Data Safety Monitoring Board or Advisory Board for the Tau Consortium and Janssen Research & Development LLC, paid to his institution; and philanthropic support from the Epstein Family Alzheimers Research Collaboration, paid to his institution. John Fisk reports no disclosures. Andrew Frank reports consulting for Eli Lilly Canada, Eisai Canada, and Novo Nordisk, paid to him. Aravind Ganesh reports grants from the Alzheimer Society of Canada and Alzheimer Society of Alberta and Northwest Territories, paid to his institution; and consulting for Biogen and Eisai, paid to him. Jodie Gawryluk reports no disclosures. Linda Grossman reports no disclosures. Arthur Harrison reports no disclosures. Alexandre Henri-Bhargava reports consulting for Eisai Canada and Eli Lilly, paid to him; contracts for clinical trials with Novo Nordisk, Cerevel, Anavex, IntelGenX, and Green Valley (Shanghai), paid to his institution; honoraria from the Canadian Coalition for Seniors Mental Health, paid to him; leadership in the Consortium of Canadian Centres for Clinical Cognitive Research and the Canadian Neurological Society, unpaid; and other financial or non-financial interests through the Neil and Susan Manning Cognitive Health Initiative, paid to his institution. Zahinoor Ismail reports consulting for CADTH, Eisai, Lilly, Lundbeck, Novo Nordisk, Otsuka, and Roche, paid to him. Inbal Itzhak reports no disclosures. Manish Joshi reports consulting for Eisai, Biogen, Eli Lilly, and Clario, paid to him. Edeltraut Kroger reports no disclosures. Sanjeev Kumar reports no disclosures. Robert Laforce reports consulting for Eisai and Eli Lilly, paid to him. Krista Lanctot reports grants from the Canadian Institutes of Health Research, Alzheimers Drug Discovery Foundation, Weston Foundation, Alzheimers Association (US), and Pooler Charitable Fund, paid to her institution; contracts with Cerevel and BioXcel, paid to her institution; consulting for Boehringer Ingelheim, Bright Minds, Bristol Myers Squibb, Cerevel, Eisai Co. Ltd, Exciva, Ironshore Pharmaceuticals, Kondor Pharma, H Lundbeck A/S, Novo Nordisk, and Praxis Therapeutics, paid to her; honoraria from Novo Nordisk, H Lundbeck, and Eisai, paid to her; support for attending meetings or travel from H Lundbeck and Eisai, paid to her institution; participation in a Data Safety Monitoring Board or advisory board for the PAS-MCI Study, unpaid; leadership in the American Association of Geriatric Psychiatry, unpaid; and receipt of equipment, materials, drugs, gifts, or services from PBG, paid to her institution. Meghan Lau reports no disclosures. Linda Lee reports consulting for Eisai, Lilly, Novo Nordisk, Lundbeck, and Roche, paid to her. Fadi Massoud reports honoraria from Astellas and Pfizer, paid to him; and consulting for Eisai and Novo Nordisk, paid to him. Sara Mitchell reports consulting for Eisai, paid to her; honoraria from Eisai and Eli Lilly, paid to her; support for attending meetings or travel from Eli Lilly, paid to her; and leadership in the Novo Nordisk Advisory Board, paid to her. Manuel Montero-Odasso reports no disclosures. Karen Myers Barnett reports no disclosures. Haakon Nygaard reports consulting for Eisai, paid to him; and participation in advisory boards for Biogen and Hoffmann-La Roche, paid to him. Stephen Pasternak reports a grant from Zywie Bio LLC, paid to his institution; consulting for Eisai, unpaid; an advisory board role for Zywie Bio LLC, unpaid; stock in Zywie Bio LLC; a patent through Zywie Bio LLC, unpaid; and leadership in the C5R Board, unpaid. Jody Peters reports no disclosures. Natalie Phillips reports no disclosures. M. Natasha Rajah reports no disclosures. Julie Robillard reports no disclosures. Kenneth Rockwood reports royalties from The Clinical Frailty Scale and the Pictorial Fit-Frail Scale, paid to his institution; honoraria from the Burnaby Family Practice, Chinese Medical Association, University of Nebraska-Omaha, the Australia New Zealand Society of Geriatric Medicine, the Atria Institute, University of British Columbia, McMaster University, and Fraser Health Authority, paid to him; a US patent application submitted for Electronic Goal Attainment Scaling (patent number US20230402138A1); consulting for EIP Pharma Inc., the ADMET-2 advisory board (Johns Hopkins), and the Wake Forest University Medical School Centre advisory board, unpaid; advisory board roles with Ardea Outcomes, Danone, Hollister, INmune, Novartis, Takeda, and Nutricia, unpaid. Pedro Rosa-Neto reports no disclosures. Dallas Seitz reports a grant from the University Health Foundation - Alberta Roche Collaboration in Health, Alzheimers Association, and Alzheimer Society of Canada, paid to his institution; honoraria from the Canadian Coalition for Seniors Mental Health, Alberta Health Services, and Recovery Alberta, paid to him; and leadership on the Board of Directors for the Alzheimer Society of Alberta and Northwest Territories, unpaid. Eric Smith reports grants from the Canadian Institutes of Health Research, Weston Family Foundation, and Weston Brain Institute, paid to his institution; contracts for clinical trials from Biogen, paid to his institution; contracts with Sense Diagnostics and SFJ Pharmaceuticals, paid to his institution; royalties from UpToDate and UTI Limited Partnership, paid to him; consulting for Eisai, Eli Lilly, and Alnylam, unpaid; and participation in a Data Safety and Monitoring Board for NINDS, paid to him. Jean-Paul Soucy reports grants from the Weston Foundation and Canadian Institutes of Health Research, paid to his institution; a contract with Charles River, paid to his institution; and consulting for Biogen, paid to him. Shanna Trenaman reports being a patient advisor for a Delphi panel developing best practices for antipsychotic use in long-term care, unpaid. Cheryl Wellington reports grants from the Heart and Stroke Foundation of Canada, BrightFocus Foundation, and Cure Alzheimer Fund, paid to her institution; and consulting for NewAmsterdam Pharma, paid to her. Aicha Zadem reports no disclosures.
Funding Statement
The Canadian Consortium on Neurodegeneration in Aging is funded by the Canadian Institutes of Health Research (Grants: CNA 137794, CNA 163902, BDO-148341) with support from partner organizations (Alberta Prion Research Institute, Alberta Innovates, Alzheimer Research UK, Alzheimer Society of Canada, Brain Canada, Canadian Nurses Foundation, Centre for Aging + Brain Health Innovation, Consortium for the Early Identification of Alzheimers Disease, Eli Lilly, Fonds de recherche du Quebec Sante, Hypertension Canada, Michael Smith Foundation for Health Research, New Brunswick Health Research Foundation, Nova Scotia Health Research Foundation, Ontario Brain Institute, Pfizer Canada Inc., Robin and Barry Picov Family Foundation, Sanofi, Saskatchewan Health Research Foundation, and Womens Brain Health Initiative).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This study uses meta-data from previously published papers. All data produced in the present work are contained in the manuscript.
